Targeting Siglec-15 may be a successful immunotherapy strategy for patients who are not responding to anti-PD-L1, as Siglec-15 expression is mutually exclusive with PD-L1 expression and independent of the PD-L1/PD-1 pathway in lung adenocarcinoma [15]. The gene discussed is CD274; the disease is lung adenocarcinoma.